Business Wire

NJ-LABVANTAGE

7.12.2022 14:01:36 CET | Business Wire | Press release

Share
LabVantage Solutions Launches Version 8.8 of its Flagship LIMS Platform

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the launch of version 8.8 of its industry-leading LabVantage LIMS platform.

LabVantage 8.8 includes multiple enhancements throughout every element of the platform. Together, they improve the accuracy, speed, usability, and security of LabVantage’s LIMS components, including its integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics.

“LabVantage 8.8 exemplifies our dual commitment to both major upgrades to our flagship LIMS platform and to continuous improvements, with the goal of providing our customers with an ever easier, safer, smarter, more flexible and more reliable system that enables the digital transformation of their laboratory,” said Mikael Hagstroem, Chief Executive Officer at LabVantage Solutions. “Over the past several years, we have added major components to our LIMS platform, including options such as SDMS, artificial intelligence (AI)-based analytics, and validated enterprise SaaS. Complementing these is our continuing attention to strengthening every aspect of the user experience, as is evident in version 8.8. For example, our new intelligent laboratory approvals substantially improve the speed and efficiency of data reviews, helping our large and diverse customer base advance towards the smart lab of the future.”

LabVantage 8.8 is available to support the more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food and beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries that rely on the LabVantage platform.

Notable among the many improvements and enhanced capabilities in LabVantage 8.8 are the following:

  • Intelligent Approvals – This new capability uses rules-based AI to streamline and speed data reviews. Reviewing large volumes of data in the LIMS is time-consuming and cumbersome. Version 8.8 enables manual approvals by exception only, allowing automatic approvals when there are no exceptions. This new feature allows users to increase the speed and efficiency of their operations against the backdrop of an ever-increasing data load.
  • Automatic Redo Calculations – Users may forget to manually re-calculate values, which affects not only final, but intermediate calculations, and can have a multi-level downstream effect on accuracy. The enhanced feature automatically triggers re-calculation when a reference is modified, allowing users to focus on the task at hand, while improving accuracy and data quality.
  • Enhanced Cybersecurity – LabVantage 8.8 provides enhanced security against OWASP Top 10 threats, and includes 3rd party certification of testing. A widely accepted standard for web application developers, OWASP Top 10 represents a broad consensus about critical cybersecurity risks. These additional safeguards incorporated in LabVantage 8.8 represent further improvements to security, providing greater peace of mind to users.
  • Accessibility – As part of ongoing efforts to better serve all of its customers, LabVantage 8.8 contains features for improved compliance with the Web Content Accessibility Guidelines (WCAG) international standard, Section 508, intended to facilitate access to the platform for users who have visual or other accessibility problems. The improved version of LabVantage Portal now has a certification of WCAG compliance, documenting a number of new features that provide increased accessibility.

LabVantage is known for its exceptional customer service and the LabVantage Professional Services team is ready to help users maximize the value of the version 8.8 enhancements.

For more information on LabVantage LIMS 8.8 click here, or email info@labvantage.com.

About LabVantage Solutions

A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005025/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business

Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release

Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me

BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release

The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS

Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release

News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai

Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release

- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye